Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1

Conditions

Polycystic Ovary Syndrome 2Papillomavirus Infections 2Vulvar Diseases 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Interventional × artenimol × Clear all
NCT06075264 2025-08-14

ART-VIN IIB

Frantz Viral Therapeutics, LLC

Phase 2 Recruiting
27 enrolled
Gynecologic

Vulvar Diseases, Papillomavirus Infections

NCT05555862 2025-05-18

anal HSIL HIV-

Frantz Viral Therapeutics, LLC

Phase 2 Active not recruiting
17 enrolled

Papillomavirus Infections

NCT06417099 2025-04-23

Efficacy of Dihydroartemisinin for Treating PCOS

Shanghai Zhongshan Hospital

Phase 2 Completed
30 enrolled

Polycystic Ovary Syndrome

NCT06842524 2025-04-20

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Shanghai Zhongshan Hospital

Phase 2 Recruiting
150 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡